|
Laxman Pai, Opalesque Asia: European health care investor Gilde Healthcare has clinched its fifth venture and growth capital fund after securing €416 million ($450 million).
The fund invests in a range of healthcare sectors including digital health, MedTech and therapeutics in Europe and North America.
The oversubscribed venture and growth capital fund attracted investments from Royal Philips, Rabo Corporate Investments, HANIEL, KfW Capital, BNP Paribas Fortis Private Equity, Belgian Growth Fund, Danish Growth Fund, and the European Investment Fund, among others.
Gilde Healthcare V will typically invest between €10m and €40m in individual companies and have a particular focus on companies that enable improved care at an affordable cost, the firm said in a statement.
Pieter van der Meer, the Managing Partner of Gilde Healthcare, said: "The healthcare landscape in Europe and the US is changing rapidly, driven by the need for more patient-centric care and more focus on value-based care."
Pieter added: "With our new fund we will continue our strategy to invest in venture and growth-stage companies developing novel solutions that enable better healthcare outcomes at reduced costs. An example is remote monitoring and home care of patients which is now more relevant than ever in the fight against COVID-19."
Recent Gilde Healthcare exits include the sale of infectious disease (including COVID-19) diagnostic platform STAT-Dx to Qiagen, the trade sale of Breath T...................... To view our full article Click here
|
RSS
